Modulating the microbiome as an approach to anticancer drug development.

Area of Science:

• Oncology
• Microbiology
• Medicinal Chemistry

Background:

• The gut microbiome influences cancer patient outcomes and treatment responses.
• Limited strategies exist for targeted microbiome modulation in cancer therapy.

Purpose of the Study:

• To identify novel gold(I) complexes with selective antimicrobial activity against non-beneficial bacteria.
• To evaluate the efficacy of these complexes in modulating the tumor and gut microbiome in vivo.
• To explore the relationship between microbiome composition, short-chain fatty acid production, and anticancer activity.

Main Methods:

• In vitro screening of gold(I) complexes for selective bacterial inhibition.
• In vivo studies in mouse models to assess microbiome changes and anticancer efficacy.
• Structure-activity relationship analysis of gold(I) complexes.
• Tumor transcriptomic analysis to identify microbiome-associated signaling pathways.

Main Results:

• Identified gold(I) complexes selectively inhibited non-beneficial bacteria without harming commensal Lactobacillus strains.
• The selected gold(I) complex modulated intratumoral and gastrointestinal microbiomes favorably in vivo.
• Anticancer efficacy correlated with microbiome composition and short-chain fatty acid metabolite production.
• Structure-activity studies revealed key components for efficacy and microbiome modulation.

Conclusions:

• Gold(I) complexes represent a promising class of microbiome-modulating agents for cancer therapy.
• Targeted microbiome modulation can enhance anticancer drug efficacy and potentially reduce side effects.
• This study provides insights into the mechanism of metal-based chemotherapeutics and their interaction with the microbiome.